Sotera Health Company (SHC) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $15.37 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: single EO supplier (United States); Concentration risk — Supplier: Russian nuclear reactors (Co-60 supply) (20.0%).
Sotera Health provides mission-critical sterilization services (Sterigenics) and lab testing (Nelson Labs) to the global healthcare industry across 62 facilities worldwide. Services are essential for regulatory compliance by medical device and pharmaceutical manufacturers... Read more
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $15.37 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: single EO supplier (United States); Concentration risk — Supplier: Russian nuclear reactors (Co-60 supply) (20.0%). Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 5.6/10, high confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle EO supplier (United States)10-K Item 1A: 'in the United States there is a single supplier for EO for our sterilization business'
- HIGHSupplierRussian nuclear reactors (Co-60 supply)20%10-K Item 1A: 'We estimate approximately 20% of our long-term supply of Co-60 will be generated by Russian nuclear reactors'
Material Events(8-K, last 90d)
- 2026-03-16Item 5.02LOWDirector Constantine S. Mihas resigned March 16, 2026 due to reduced stockholder designation rights; not related to any disagreement. Kenneth D. Krause (EVP/CFO of Rollins, Inc.) appointed Class I director effective March 16, 2026.SEC filing →
- 2026-02-24Item 5.02MEDIUMSVP and General Counsel Alex Dimitrief provided notice of departure on February 18, 2026. No reason cited; no successor named at time of filing.SEC filing →
- 2026-02-05Item 5.02LOWBoard increased size from 11 to 12 directors and appointed Richard G. Kyle (former President/CEO of The Timken Company) as Class III director effective February 4, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $15.37 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: single EO supplier (United States); Concentration risk — Supplier: Russian nuclear reactors (Co-60 supply) (20.0%). Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $14.54. Score 5.6/10, high confidence.
Take-profit target: $17.84 (+16.0% upside). Prior stop was $14.54. Stop-loss: $14.54.
Concentration risk — Supplier: single EO supplier (United States); Concentration risk — Supplier: Russian nuclear reactors (Co-60 supply) (20.0%); Leverage penalty (D/E 3.8): -1.5.
Sotera Health Company trades at a P/E of 57.2 (forward 14.8). TrendMatrix value score: 7.1/10. Verdict: Sell.
15 analysts cover SHC with a consensus score of 4.2/5. Average price target: $21.
What does Sotera Health Company do?Sotera Health provides mission-critical sterilization services (Sterigenics) and lab testing (Nelson Labs) to the...
Sotera Health provides mission-critical sterilization services (Sterigenics) and lab testing (Nelson Labs) to the global healthcare industry across 62 facilities worldwide. Services are essential for regulatory compliance by medical device and pharmaceutical manufacturers globally.